Fluvoxamine maleate

The maleate salt form of fluvoxamine, a 2-aminoethyl oxime ether of aralkylketones, with antidepressant, antiobsessive-compulsive, and antibulimic activities.

How does this medicine work?

• Fluvoxamine blocks serotonin reuptake by inhibiting the serotonin reuptake pump of the presynaptic neuronal membrane leading to an increase of serotonin levels within the synaptic cleft.
• This results in facilitated serotonergic transmission and decreased serotonin turnover leading to antidepressant and antiobsessive-compulsive effects.

What is this medication used for?

Fluvoxamine maleate tablets are indicated for the treatment of - obsessions and compulsions in patients with obsessive compulsive disorder

Contraindications

Coadministration of tizanidine, thioridazine, alosetron, or - pimozide with fluvoxamine maleate tablets is contraindicated.

Adverse reactions

Adverse reactions leading to treatment - discontinuationof the 1087 ocd and depressed patients treated with fluvoxamine - maleate Overdosage

Overdosage

• human experience worldwide exposure to fluvoxamine includes over 45,000 patients - treated in clinical trials and an estimated exposure of 50,000,000 patients - treated until end of 2005.
• Of the 539 cases of deliberate or accidental overdose involving fluvoxamine reported from this population, there were 55 deaths.
• Of these, 9 were in patients thought to be taking fluvoxamine alone and the remaining 46 were in patients taking fluvoxamine along with other drugs.

Dosage and administration

The recommended starting dose for fluvoxamine maleate tablets in - adult patients is 50 mg, administered as a single daily dose at bedtime.

How supplied

Fluvoxamine maleate tablets are available in the - following strengths, colors, imprints, and presentations: tablets 25 mg

Patient counseling information

prescribers or other health professionals should inform patients, their families, and their caregivers about the benefits and risks associated - with treatment ...

Boxed warning

Suicidality and antidepressant drugs

• Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (mdd) and other psychiatric disorders.
• Anyone considering the use of fluvoxamine maleate tablets or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older.
• Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber.
• Fluvoxamine maleate tablets are not approved for use in pediatric patients except for patients with obsessive compulsive disorder (ocd).

• Dailymed label info on Fluvoxamine maleate
• FDA Fluvoxamine maleate

Fluvoxamine maleate Resources
Latest articles Most recent articles Ongoing trials	Wikipedia

The following are antidepressant subclasses and drugs

MAO Inhibitors Isocarboxazid, Phenelzine, Tranylcypromine

SNRIs Duloxetine, Levomilnacipran, Venlafaxine

SSRIs Citalopram, Escitalopram, Fluoxetine, Fluvoxamine, Paroxetine, Sertraline, Vilazodone, Vortioxetine

Tricyclics Amitriptyline, Amoxapine, Clomipramine, Desipramine, Doxepin, Imipramine, Nortriptyline, Protriptyline, Trimipramine

Miscellaneous Bupropion, Flibanserin, Mirtazapine, Nefazodone, Trazodone